Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability ...

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...

According to the World Health Organization, tuberculosis accounts for one in three deaths among people living with HIV. In ...

HIV’s Tat protein blocks autophagy in macrophages, letting Mtb thrive. This may explain why HIV patients face higher TB risk even on ART.

A recent study by the German Center for Infection Research reveals how HIV integrates its genetic material into human DNA, potentially leading to new treatment strategies.

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human ...

The initiative is part of a broader campaign to ensure a healthy and stigma-free working environment within the justice ...

Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...

A new Northwestern Medicine study has uncovered a surprising molecular link between HIV-1 and a protein fragment associated with Alzheimer's disease, according to findings published in the Proceedings ...